A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,501–3,600 of 3,965
Macrolides and Interstitial Lung Diseases
Hara, Y., & Kaneko, T. (2024) · Progress in inflammation research · doi:10.1007/978-3-031-42859-3_8
Idiopathic Pulmonary Fibrosis Comorbid With Mediastinal Small Cell Carcinoma: A Clinical Dilemma
Shakir, M. H., Basit, S. A., Ray, B. K., et al. (2024) · Cureus · doi:10.7759/cureus.53578
La fibrosis pulmonar vista desde sus primeros casos publicados en México
Buendía-Roldán, I. (2024) · NCT Neumología y Cirugía de Tórax · doi:10.35366/114818
Biomarkers and phenotype concepts in sarcoidosis care
Schimmelpennink, M. C. (2024) · Utrecht University Repository (Utrecht University) · doi:10.33540/2085
Adoptive transfer of CD49a + Tissue resident memory cells reverses pulmonary fibrosis in micePreprint
Collins, S. L., Chan‐Li, Y., Shenderov, K., Gillich, A., Nelson, A. M., Loube, J., Mitzner, W., Powell, J. D., & Horton, M. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.13.584814
Progress in Drug Therapy for Idiopathic Pulmonary Fibrosis
洪, 阳. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441004
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623160
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623163
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623166
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617857
Luo, H., Wang, S., Yang, G., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4789972
Lin, M., Wang, J., Wei, J., Yao, Y., Tang, C., Jin, W., Yuan, W., & Lv, Y. (2024) · European Journal of Inflammation · doi:10.1177/1721727x241247761
Treatment of Interstitial Lung Disease in Systemic Sclerosis
Elhaï, M., Crestani, B., Muraru-Carbrune, M.-S., & Allanore, Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_26
Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy
Silver, K., Highland, K. B., & Silver, R. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_55
Pugashetti, J. V., & Wolters, P. J. (2024) · CHEST Journal · doi:10.1016/j.chest.2023.12.023
Qiu, W., Wang, Q., Zhang, Y., Cao, X., Zhao, L., Cao, L., Sun, Y., Yang, F. L., Guo, Y., Sui, Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4823578
Ray, R. S., Bhowmik, R., Shyamal, S. S., Manaithiya, A., Gong, W., Parkkila, S., & Aspatwar, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.26.595932
What has antifibrotic therapy changed for patients with idiopathic pulmonary fibrosis
Кузубова, Н. А., Titova, O. N., Sklyarova, D. B., & Va, V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-105 · Cited by 1
Bastan, F., & Kazemeini, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4868082
Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
Țău, V., Antal, A. Z., Antohi, P. V., Stoian, I. A., Pintilie, A.-L., Trofor, A. C., & Crișan-Dabija, R. A. (2023) · Pneumologia · doi:10.2478/pneum-2024-0014
A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow‐Up
Degirmenci, G., & Satıcı, C. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13797
Outcome after nintedanib therapy for fibrosing interstitial lung disease in patients without dyspneaPreprint
Okamoto, M., Yanagihara, T., Fujimoto, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4513070/v1
Cheng, W.-C., Chen, P. Y., Zhang, X., Chang, Y., Tan, K., & Lin, T. C. C. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2371150 · Cited by 1
Matsui, Y., Abe, M., Uematsu, Y., Onozato, Y., Yamamoto, T., & Iwata, T. (2024) · The Journal of the Japanese Association for Chest Surgery · doi:10.2995/jacsurg.38.446
Shah, N. (2024) · Diseases · doi:10.3390/diseases12070155
“While nintedanib and pirfenidone are effective in slowing lung function decline, they show limited efficacy in alleviating symptoms or improving HRQOL in IPF patients [18,19].”
BackgroundZhu, D., Zhang, J., Guo, P., Tao, S., Zeng, M., Zheng, X., & Feng, W. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4889003
Martka, M. M., Skorupska, M., Aleksiej, A., et al. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.52930
Autoimmune interstitial lung disease
Herrán, M., Galindo, J. L., Chaves, J. J., Carrillo-Bayona, J. A., Polo, F. C., Rojas, M., & Anaya, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00007-2
Clinical Trials in Lung Transplantation
Kotecha, S., Ivulich, S., & Snell, G. I. (2023) · Organ and tissue transplantation · doi:10.1007/978-3-319-20788-9_50-1
Extent of Alveolar Collapse in Expiratory CT as a Prognostic Marker in Idiopathic Pulmonary FibrosisPreprint
Scharm, S. C., Schaefer‐Prokop, C. M., Schreuder, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4704934/v1
Automatic diagnostic support for diagnosis of pulmonary fibrosisPreprint
Pal, R., Barney, A. M., Sgalla, G., et al. (2024) · medRxiv · doi:10.1101/2024.08.14.24312012
TRP channels in respiratory disorders
Bonvini, S. J., Wortley, M. A., & Belvisi, M. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18653-0.00030-7
Huang, J., Su, L., Wu, D., & Yuan, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4820805/v1
Matsushima, R., Fujino, K., Motooka, Y., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15418
Reyes-Cartes, F. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2024.05.004 · Cited by 2
Marega, M., Mejdoubi‐Charef, N., Wiegard, D., Khan, M. M., Bartkuhn, M., Gambs, L., Procida‐Kowalski, T., Wilhelm, J., Vásquez‐Pacheco, E., Noori, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618798
Clinical Trials in Lung Transplantation
Kotecha, S., Ivulich, S., & Snell, G. I. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-030-36123-5_50
AD-214 anti CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosisPreprint
Lynch, J. P., Organ, L. A., Tomusange, K., Kowalczyk, L., Hartman, D., Tester, A. M., Hosking, C. G., & Foley, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5196248/v1
Platelet indices and idiopathic pulmonary fibrosis: a multivariable mendelian randomization studyPreprint
Zheng, Y., Liang, Y., Zhu, L., Li, C., Zang, N., Wang, T., Pang, L., Lv, X., & Liu, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-5035687/v1
Larson‐Casey, J. L., VU-TICAR, N. N., Craver, J., Migliaccio, C. T., Holian, A., Kendall, R. L., Albright, J. M., & Venosa, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00170-4
Diffuse parenchymal lung disease
Paramothayan, D. S. (2019) · doi:10.1002/9781394322152.ch7
Anchoring Patient Voices to Shape the Future of Patient-reported Outcomes
Grant-Orser, A., & Guler, S. A. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202410-1028ed
Arkhangelskaya, E. E., Lyamina, S., Kozhevnikova, E. O., Козлова, И. В., Shapovalova, T. G., & Yurenev, G. L. (2024) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2024-14-6-405-418 · Cited by 1
Heart and lung transplantation
Doi, A., Marasco, S., Patel, H. C., Paraskeva, M. A., & McGiffin, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22148-4.00002-2
Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis
O’Mahony, A. T., Waldron, M., Henry, P. J., Shet, S. S., O’Regan, P. W., Bennett, D. M., Ryan, D. J., Maher, M. M., & Henry, M. T. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.106759
From Liver Insights to Lung Innovations: FGF21 and Idiopathic Pulmonary Fibrosis
Coba, A. J. G., Barnes, J. W., & Krick, S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-1975ed · Cited by 1
Heart, lungs, and statins: is it an easy cohabitation? Pitfalls and controversies
Polito, D., Segreti, A., Piscione, M., Vespasiano, F., Nafisio, V., Cavallari, I., Ussia, G. P., Incalzi, R. A., & Grigioni, F. (2024) · Minerva Respiratory Medicine · doi:10.23736/s2784-8477.24.02137-5
栗, 萱. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123077
Aspects of diagnosis and providing care for interstitial lung diseases in a specialized center
Викторович, Л. И., Glushkova, T. V., Михайловна, Т. Н., & Esaulova, N. A. (2024) · PULMONOLOGIYA · doi:10.18093/0869-0189-2024-34-6-920-929
State of the ART: Drug Screening Reveals Artesunate as a Promising Anti-Fibrosis Therapy
Qiao, Y., Liang, J., & Jiang, D. (2024) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2024.10023
Molekulare Diagnostik der interstitiellen Lungenerkrankungen
Jonigk, D. D., Verleden, S. E., & Länger, F. P. (2024) · Springer eBooks · doi:10.1007/978-3-662-67073-6_36
Insight into the efficacy and safety of pirfenidone: The treatment of idiopathic pulmonary fibrosis
Xu, L., Yu, Y., & Cen, L.-S. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i14.98769 · Cited by 1
(2000) · Time to knit · doi:10.1016/s1155-195x(23)41902-0
(2000) · Time to knit · doi:10.1016/s0084-3873(15)00249-7
Interstitial Lung Diseases (ILDS)
Borkar, Y. R., Salve, M. S. K., & Kitukale, M. D. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-23024
(2000) · Time to knit · doi:10.1016/j.ccol.2023.02.001
(2000) · Time to knit · doi:10.1016/s1155-195x(24)45836-2
(2000) · Time to knit · doi:10.1016/s1155-195x(20)61247-6
Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications
Kulkarni, T., Santiaguel, J. M., Aul, R., Harnett, M. D., Krop, J. S., Chen, M. J., Graham, C. S., & Maher, T. M. (2025) · ERJ Open Research · doi:10.1183/23120541.01142-2024
Aronson, K. I., Raghu, G., Gupta, S., Ko, J., Devine, J., & Swigris, J. J. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100145 · Cited by 1
Self-citationThe Role of HSP47 in Heart Failure and Other Fibrotic Diseases
段, 荣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152455
Herrmann, A., & Parr, D. G. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-263966 · Cited by 1
4. Idiopathic Pulmonary Fibrosis (IPF) -Up-to-Date-
Suda, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.508
Igai, Y. (2024) · Journal of Japan Academy of Nursing Science · doi:10.5630/jans.44.1146
Leelam, C. P., & Vemula, M. (2020) · International Journal of Advanced Research in Medicine · doi:10.22271/27069567.2020.v2.i2a.616 · Cited by 1
Radiologic: Pathologic correlation in interstitial lung diseases
Satish, G., & Karri, A. (2019) · International Journal of Radiology and Diagnostic Imaging · doi:10.33545/26644436.2019.v2.i2b.444
Les traitements antifibrosants : où en sommes-nous 10 ans après ?
Hindré, R., & Uzunhan, Y. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.04.002
Chang, A., Sia, J. T., Casper, G. E., Wood, S. R., Markham, L., Westhoff, L. L., Saxton, A. J., Snow, G. L., Ry, P. M. V., & Raghu, G. (2025) · European Respiratory Journal · doi:10.1183/13993003.02317-2024
Timing of lung transplant evaluation: considerations, barriers and alternatives
van der Ploeg, E. A., Hylkema, T. H., & Gan, C. T. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001176
Rebuttal From Drs Marinescu and Ryerson
Marinescu, D.-C., & Ryerson, C. J. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.12.008
Imaging of Diffuse Lung Diseases
Mura, R., Gallone, V. I., Roberti, C., Ledda, R. E., & Sverzellati, N. (2025) · Medical radiology · doi:10.1007/174_2025_575
The Future of Precision Medicine in Interstitial Lung Disease
Adams, T. N., Patel, C., & Gulati, M. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_11
Big Data: Pearls and Pitfalls for Precision Medicine in Interstitial Lung Disease
Kaul, B., Collard, H. R., & Petersen, L. A. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_10
Borghetti, P., Angelillo, R. M. D. A., Facheris, G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5239531
Kronborg-White, S. B., Jensen, J. H., Bendstrup, E. M., & Prior, T. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099664
Effectiveness Of Antifibrotic Treatment in Real-World Patients with Progressive Pulmonary FibrosisPreprint
Niitsu, T., Fukushima, K., Komukai, S., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5269510
Andresen, B. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103610
Essential Interstitial Lung Disease Management for the Primary Care Provider
Grant-Orser, A. (2025) · Canadian Primary Care Today · doi:10.58931/cpct.2025.3138
Study population: Who and why them?
Smith, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90391-2.00023-3
Yan, L., Li, J.-H., Zhang, A., Li, H., Pang, B., Meng, D.-Y., Fu, Q., Du, L.-J., & Su, Y. (2025) · Hereditas · doi:10.1186/s41065-025-00464-x
RD-LIVES: A Living Evidence Synthesis System for Rare Disease Treatment Efficacy and Safety.
Wang, J., Li, H., & Liu, H. (2025) · Europe PMC (PubMed Central)
Parikh, M., Soni, A., & Gandhi, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22300-6.00019-x
Idiopathic pulmonary fibrosis in a patient with rheumatoid arthritis
Dobrianskyi, D. V., Tahiieva, N., Khranovska, M. S., et al. (2025) · Infusion & Chemotherapy · doi:10.32902/2663-0338-2025-2-45-49
Idiopathic pulmonary fibrosis in a patient with rheumatoid arthritis
Dobrianskyi, D. V., Tahiieva, N., Khranovska, M. S., et al. (2025) · Infusion & Chemotherapy · doi:10.32902/2663-0338-8-2025-2-45-49
Sadeghi, S., Madanchi, H., Karami, M., Yazdian‐Robati, R., Seyedabadi, M., & Mohammadi, H. (2025) · Egyptian Journal of Bronchology · doi:10.1186/s43168-025-00413-2
Conti, M., Casara, A., Turato, G., Baraldo, S., Tinè, M., Semenzato, U., Cocconcelli, E., Biondini, D., Damin, M., Saetta, M. P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541645
The Changing Landscape of Lung Transplantation
Sadeleer, L. D., Godinas, L., Dupont, L., Ceulemans, L. J., Vos, R., & Bos, S. (2025) · Respiratory The American Medical Journal · doi:10.33590/respiramj/zkbr4615 · Cited by 2
Progress of Urinary Proteome Research in Respiratory Diseases
Wu, J., Wang, S., & Qin, X. (2025) · Springer eBooks · doi:10.1007/978-981-96-7886-0_16
A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults
Maher, T. M., Chen, M. J., Korth, C. C., Elenko, E., Harnett, M. D., Garg, V., & Graham, C. S. (2025) · ERJ Open Research · doi:10.1183/23120541.00469-2025 · Cited by 1
Lee, J. H., Jang, J. H., Kim, S. Y., Park, M. S., Chung, M. P., Yoo, H., Jeong, S. H., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e212 · Cited by 1
Noroozi, H., & Pakzad, R. (2025) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x373765250710105821
Navigating the Alphabet Soup of Interstitial Lung Diseases ( ILD ): The Role of Pharmacists
Martirosov, A. L., Abdalla, M., Fleischman, M. E., Foster, B., Gonzales, J. P., Lipari, M., Malesker, M. A., Smith, Z., Wilken, L. A., & Williams, D. M. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70089
(2025) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-24.1.29
Johnson, C. R., Podolanczuk, A. J., Danoff, S. K., Kreider, M. E., & Anderson, M. R. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2428vp
Derseh, H. B., Davies, A., Young, A., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03803-w
Behr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00570-2025 · Cited by 2
Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging
Ghazaiean, M., Riss, P. J., Mardanshahi, A., & Molavipordanjani, S. (2025) · Molecular Imaging and Biology · doi:10.1007/s11307-025-02038-9 · Cited by 1
An Explainable Cryobiopsy AI Model, CRAI, to Predict Progression in Interstitial PneumoniaPreprint
Uegami, W., Okoshi, E. N., Lami, K., et al. (2025) · medRxiv · doi:10.1101/2025.08.06.25333181
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.